Circulating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women
Sabina Rinaldi,Laure Dossus,Pekka Keski-Rahkonen,Agneta Kiss,Anne-Sophie Navionis,Carine Biessy,Ruth Travis,Elisabete Weiderpass,Isabelle Romieu,Anne Kirstine Eriksen,Anne Tjonneland,Marina Kvaskoff,Marianne Canonico,Thérèse Truong,Verena Katzke,Rudolf Kaaks,Alberto Catalano,Salvatore Panico,Giovanna Masala,Rosario Tumino,Marko Lukic,Karina Standahl Olsen,Raul Zamora-Ros,Carmen Santiuste,Amaia Aizpurua Atxega,Marcela Guevara,Miguel Rodriguez-Barranco,Maria Sandstrom,Joakim Hennings,Martin Almquist,Elom Aglago Kouassivi,Sofia Christakoudi,Marc Gunter,Silvia Franceschi,Pekka Keski‐Rahkonen,Anne‐Sophie Navionis,Raul Zamora‐Ros,Miguel Rodriguez‐Barranco
DOI: https://doi.org/10.1002/ijc.34872
2024-02-16
International Journal of Cancer
Abstract:What's new? Thyroid cancer occurs more often in women than men, suggesting that sex hormones may contribute to the disease. Here, the authors investigated the association between circulating sex steroid hormones, sex hormone binding globulin protein (SHBG), and the risk of thyroid cancer in both men and women using data from the European Prospective Investigation into Cancer and nutrition (EPIC). They measured concentrations of testosterone, androstenedione, dehydroepiandrosterone, estradiol, estrone and progesterone (in pre‐menopausal women only), as well as SHBG. Overall, they did not detect a strong association between hormones, SHBG and thyroid cancer incidence. Thyroid cancer (TC) is substantially more common in women than in men, pointing to a possible role of sex steroid hormones. We investigated the association between circulating sex steroid hormones, sex hormone binding globulin (SHBG) and the risk of differentiated TC in men and women within the European Prospective Investigation into Cancer and nutrition (EPIC) cohort. During follow‐up, we identified 333 first primary incident cases of differentiated TC (152 in pre/peri‐menopausal women, 111 in post‐menopausal women, and 70 in men) and 706 cancer‐free controls. Women taking exogenous hormones at blood donation were excluded. Plasma concentrations of testosterone, androstenedione, dehydroepiandrosterone, estradiol, estrone and progesterone (in pre‐menopausal women only) were performed using liquid chromatography/mass spectrometry method. SHBG concentrations were measured by immunoassay. Odds ratios (ORs) were estimated using conditional logistic regression models adjusted for possible confounders. No significant associations were observed in men and postmenopausal women, while a borderline significant increase in differentiated TC risk was observed with increasing testosterone (adjusted OR T3 vs T1: 1.68, 95% CI: 0.96–2.92, ptrend = .06) and androstenedione concentrations in pre/perimenopausal women (adjusted OR T3 vs T1: 1.78, 95% CI: 0.96–3.30, ptrend = .06, respectively). A borderline decrease in risk was observed for the highest progesterone/estradiol ratio (adjusted OR T3 vs T1: 0.54, 95% CI: 0.28–1.05, ptrend = .07). Overall, our results do not support a major role of circulating sex steroids in the etiology of differentiated TC in post‐menopausal women and men but may suggest an involvement of altered sex steroid production in pre‐menopausal women.
oncology